Terms: = Pancreatic cancer AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB AND Clinical Outcome
20 results:
1. NSD3, a member of nuclear receptor-binding SET domain family, is a potential prognostic biomarker for pancreatic cancer.
Xiong Q; Zhou Y; Zhang S; Zhang Y; Xu Y; Yang Y; Zhou C; Zeng Z; Han J; Zhu Q
Cancer Med; 2023 May; 12(9):10961-10978. PubMed ID: 37062069
[TBL] [Abstract] [Full Text] [Related]
2. Tenascin-C affects invasiveness of egfr-mutated lung adenocarcinoma through a putative paracrine loop.
Schlensog M; Ruehlmann AC; Haeberle L; Opitz F; Becher AK; Goering W; Buth J; Knoefel WT; Ladage D; Meyer A; Esposito I
Biochim Biophys Acta Mol Basis Dis; 2023 Jun; 1869(5):166684. PubMed ID: 36878305
[TBL] [Abstract] [Full Text] [Related]
3. Improving Gemcitabine Sensitivity in pancreatic cancer Cells by Restoring miRNA-217 Levels.
Panebianco C; Trivieri N; Villani A; Terracciano F; Latiano TP; Potenza A; Perri F; Binda E; Pazienza V
Biomolecules; 2021 Apr; 11(5):. PubMed ID: 33925948
[TBL] [Abstract] [Full Text] [Related]
4. Anti-egfr chimeric antigen receptor-modified T cells in metastatic pancreatic carcinoma: A phase I clinical trial.
Liu Y; Guo Y; Wu Z; Feng K; Tong C; Wang Y; Dai H; Shi F; Yang Q; Han W
Cytotherapy; 2020 Oct; 22(10):573-580. PubMed ID: 32527643
[TBL] [Abstract] [Full Text] [Related]
5. Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma.
Abdel-Wahab R; Varadhachary GR; Bhosale PR; Wang X; Fogelman DR; Shroff RT; Overman MJ; Wolff RA; Javle M
J Hematol Oncol; 2018 May; 11(1):71. PubMed ID: 29843755
[TBL] [Abstract] [Full Text] [Related]
6. Practical recommendation for rash and diarrhea management in Indian patients treated with tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.
Parikh P; Prabhash K; Naik R; Vaid AK; Goswami C; Rajappa S; Noronha V; Joshi A; Chacko RT; Aggarwal S; Doval DC
Indian J Cancer; 2016; 53(1):87-91. PubMed ID: 27146751
[TBL] [Abstract] [Full Text] [Related]
7. Polymorphisms in epidermal growth factor receptor (egfr) and AKT1 as possible predictors of clinical outcome in advanced non-small-cell lung cancer patients treated with egfr tyrosine kinase inhibitors.
Zhang X; Fan J; Li Y; Lin S; Shu P; Ni J; Qin S; Zhang Z
Tumour Biol; 2016 Jan; 37(1):1061-9. PubMed ID: 26269114
[TBL] [Abstract] [Full Text] [Related]
8. Combining clinicopathological predictors and molecular biomarkers in the oncogenic K-RAS/Ki67/HIF-1α pathway to predict survival in resectable pancreatic cancer.
Qin R; Smyrk TC; Reed NR; Schmidt RL; Schnelldorfer T; Chari ST; Petersen GM; Tang AH
Br J Cancer; 2015 Feb; 112(3):514-22. PubMed ID: 25584484
[TBL] [Abstract] [Full Text] [Related]
9. outcome of gemcitabine plus molecular targeted agent for treatment of pancreatic cancer: a meta-analysis of prospective phase III studies.
Chen L; Zhang M; Luo S
Tumour Biol; 2014 Nov; 35(11):11551-8. PubMed ID: 25129442
[TBL] [Abstract] [Full Text] [Related]
10. Anti-pancreatic cancer deliverables from sea: first-hand evidence on the efficacy, molecular targets and mode of action for multifarious polyphenols from five different brown-algae.
Aravindan S; Delma CR; Thirugnanasambandan SS; Herman TS; Aravindan N
PLoS One; 2013; 8(4):e61977. PubMed ID: 23613993
[TBL] [Abstract] [Full Text] [Related]
11. Ultraviolet enhances the sensitivity of pancreatic cancer cells to gemcitabine by activation of 5' AMP-activated protein kinase.
Adachi S; Yasuda I; Kawaguchi J; Yamauchi T; Nakashima M; Itani M; Nakamura M; Yoshioka T; Moriwaki H; Kozawa O
Biochem Biophys Res Commun; 2011 Oct; 414(1):53-9. PubMed ID: 21945432
[TBL] [Abstract] [Full Text] [Related]
12. Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers.
Witkiewicz AK; Dasgupta A; Sammons S; Er O; Potoczek MB; Guiles F; Sotgia F; Brody JR; Mitchell EP; Lisanti MP
Cancer Biol Ther; 2010 Jul; 10(2):135-43. PubMed ID: 20431349
[TBL] [Abstract] [Full Text] [Related]
13. Epidermal growth factor receptor (egfr) intron 1 polymorphism and clinical outcome in pancreatic adenocarcinoma.
Frolov A; Liles JS; Kossenkov AV; Tzeng CW; Jhala N; Kulesza P; Varadarajulu S; Eloubeidi M; Heslin MJ; Arnoletti JP
Am J Surg; 2010 Sep; 200(3):398-405. PubMed ID: 20409526
[TBL] [Abstract] [Full Text] [Related]
14. Coexpression of egfr and HER-2 in pancreatic ductal adenocarcinoma: a comparative study using immunohistochemistry correlated with gene amplification by fluorescencent in situ hybridization.
Dancer J; Takei H; Ro JY; Lowery-Nordberg M
Oncol Rep; 2007 Jul; 18(1):151-5. PubMed ID: 17549361
[TBL] [Abstract] [Full Text] [Related]
15. pancreatic cancer epidermal growth factor receptor (egfr) intron 1 polymorphism influences postoperative patient survival and in vitro erlotinib response.
Tzeng CW; Frolov A; Frolova N; Jhala NC; Howard JH; Vickers SM; Buchsbaum DJ; Heslin MJ; Arnoletti JP
Ann Surg Oncol; 2007 Jul; 14(7):2150-8. PubMed ID: 17453292
[TBL] [Abstract] [Full Text] [Related]
16. Synergistic effects of interferon-alpha in combination with chemoradiation on human pancreatic adenocarcinoma.
Ma JH; Patrut E; Schmidt J; Knaebel HP; Büchler MW; Märten A
World J Gastroenterol; 2005 Mar; 11(10):1521-8. PubMed ID: 15770730
[TBL] [Abstract] [Full Text] [Related]
17. Expression of ERRP in normal and neoplastic pancreata and its relationship to clinicopathologic parameters in pancreatic adenocarcinoma.
Feng J; Adsay NV; Kruger M; Ellis KL; Nagothu K; Majumdar AP; Sarkar FH
Pancreas; 2002 Nov; 25(4):342-9. PubMed ID: 12409827
[TBL] [Abstract] [Full Text] [Related]
18. Enhanced mRNA expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in breast carcinomas is correlated with adverse prognosis.
Nakopoulou L; Giannopoulou I; Stefanaki K; Panayotopoulou E; Tsirmpa I; Alexandrou P; Mavrommatis J; Katsarou S; Davaris P
J Pathol; 2002 Jul; 197(3):307-13. PubMed ID: 12115876
[TBL] [Abstract] [Full Text] [Related]
19. Immunohistochemical expression of transforming growth factor alpha and epidermal growth factor receptor in pancreatic endocrine tumors.
Srivastava A; Alexander J; Lomakin I; Dayal Y
Hum Pathol; 2001 Nov; 32(11):1184-9. PubMed ID: 11727256
[TBL] [Abstract] [Full Text] [Related]
20. An immunohistochemical study of the c-erbb-2 oncogene product in intraductal mucin-hypersecreting neoplasms and in ductal cell carcinomas of the pancreas.
Satoh K; Sasano H; Shimosegawa T; Koizumi M; Yamazaki T; Mochizuki F; Kobayashi N; Okano T; Toyota T; Sawai T
Cancer; 1993 Jul; 72(1):51-6. PubMed ID: 8099533
[TBL] [Abstract] [Full Text] [Related]
